Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Bacigalupo A, Brand R, Oneto R, Bruno B, Socié G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy—The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69–80.

    Article  CAS  Google Scholar 

  2. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947–50.

    Article  CAS  Google Scholar 

  3. Bacigalupo A. Bone marrow transplantation for severe aplastic anemia. Hematol Oncol Clin N Am. 2014;28:1145–55.

    Article  Google Scholar 

  4. Bacigalupo A, Sica S. Alternative donor transplants for severe aplastic anemia: current experience. Semin Hematol. 2016;53:115–19.

    Article  Google Scholar 

  5. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease, relapse-free survival after allogeneic stem cell transplantation. Blood. 2015;125:1333–38.

    Article  CAS  Google Scholar 

  6. Gupta V, Eapen M, Brazauskas R, Carreras J, Aljurf M, Gale RP, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010;95:2119–25.

    Article  Google Scholar 

  7. Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, et al. In vivo B-cell depletion with rituximab for alternative donor hematopoietic SCT. Bone Marrow Transplant. 2012;47:101–6.

    Article  CAS  Google Scholar 

  8. Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:901–7.

    Article  CAS  Google Scholar 

  9. Liu W, Wu D, Hu T, Ye B. Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases. Int J Clin Exp Med. 2015;8:14080–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Liu W, Hu Z, Lin S, He J, Zhou Y. Systemic lupus erythematosis with severe aplastic anemia successfully treated with rituximab and antithymocyte globulin. Pak J Med Sci. 2014;30:449–51.

    PubMed  PubMed Central  Google Scholar 

  11. Gomez-Almaguer D, Jaime-Perez JC, Ruiz-Arguelles GJ. Antibodies in the treatment of aplastic anemia. Arch Immunol Ther Exp (Warsz). 2012;60:99–106.

    Article  CAS  Google Scholar 

  12. Takamatsu H, Yagasaki H, Takahashi Y, Hama A, Saikawa Y, Yachie A, et al. Aplastic anemia successfully treated with rituximab: the possible role of aplastic anemia-associated autoantibodies as a marker for response. Eur J Haematol. 2011;86:541–5.

    Article  CAS  Google Scholar 

  13. Dufour C, Svahn J, Bacigalupo A, on Behalf of the Severe Aplastic Anemia Working Party of the EBMT. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 2013;48:174–77.

    Article  CAS  Google Scholar 

  14. Bacigalupo A, Socié G, Lanino E, Prete A, Locatelli F, Locasciulli A, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Hematologica . 2010;95:976–82.

    Article  CAS  Google Scholar 

  15. Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20:1711–6.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the contribution of Justin D. Gatwood, PhD, MPH to this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katie S. Gatwood.

Ethics declarations

Conflict of interest

KSG and BNS serve on a Speakers Bureau for Jazz Pharmaceuticals. The remaining authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gatwood, K.S., Culos, K.A., Binari, L.A. et al. Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia. Bone Marrow Transplant 53, 795–799 (2018). https://doi.org/10.1038/s41409-018-0124-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0124-6

Search

Quick links